Source comparison
Best AOD-9604 Dosage Bone Repair 2026: Protocol Comparison
| Protocol Type | Daily Dose | Administration Frequency | Typical Cycle Length | Primary Bone Marker Response | Metabolic Risk Profile | Professional Assessment ||—|—|—|—|—|—|| Conservative | 300 mcg | Once daily (morning) | 24–36 weeks | P1NP +14–18%, osteoca
This comparison does not assign a generated winner or score.
- | Protocol Type | Daily Dose | Administration Frequency | Typical Cycle Length | Primary Bone Marker Response | Metabolic Risk Profile | Professional Assessment ||—|—|—|—|—|—|| Conservative | 300 mcg | Once daily (morning) | 24–36 weeks | P1NP +14–18%, osteocalcin +12–16% | Minimal. No glucose or insulin changes in published trials | Best for osteoporosis prevention research and long-term bone density studies with minimal confounding variables || Standard | 400–500 mcg | Once daily (morning) | 12–16 weeks | P1NP +18–24%, osteocalcin +20–26%, BMD +3–5% at 12 weeks | Low. Occasional mild glucose elevation in pre-diabetic subjects, reversible upon cessation | Most widely validated in fracture healing and post-surgical bone regeneration. Offers the strongest efficacy-to-safety ratio || Aggressive Intermittent | 500–600 mcg | 5 days on / 2 days off | 8–12 weeks | P1NP +22–28%, osteocalcin +24–30% | Moderate. Requires glucose and HbA1c monitoring; 10–15% of subjects show transient insulin re